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In vitro lymphocyte blastogenic responses to the commonly employed mito-
gens, phytohemagglutinin, pokeweed, and concanavalin A, were evaluated when
adenine arabinoside (ara-A) in a concentration of 3 ,g/ml was added to the
cultire materials. Similarly, blastogenic and cytotoxic responses to cell cultures
persistently infected with herpes simplex virus 1, herpes simplex virus 2, and
varicella-zoster virus were determined in the presence of ara-A. No depression of
these cellular immune responses by ara-A was demonstrated. This was in
contrast to the effect of cytosine arabinoside, which at a concentration of 3 ,g/ml
severely inhibited these immune responses. Further studies examined lympho-
cyte blastogenic responses to the mitogens and blastogenic and cytotoxic
responses specific for the herpes group virus infecting patients who were
subsequently treated with ara-A; determinations were made before, during, and
after treatment. In vitro responses during and after treatment with ara-A were
unchanged or often enhanced as compared to pretreatment values. Therefore, the
antiviral chemotherapeutic agent, ara-A, does not appear to depress the host's
cellular immune responses, which are vital to successful elimination of invading
herpes group viruses.
Advances in the control of viral disease have
depended on the development of vaccines and
more recently on antiviral chemotherapy (2).
The efficacy of antiviral chemotherapeutic
agents has been primarily based on clinical
response and the ability of an agent to eradicate
the virus. However, full recovery from the viral
disease still appears to require intact host
defense mechanisms. Such host defense against
viral infection involves a complex interplay
between antibody and cell-mediated responses,
and, although the relative importance of cellu-
lar immunity has not been fully delineated, the
severe or fatal infections in children with
thymic deficiency syndromes or patients on
immunosuppressive therapy suggest that cellu-
lar immunity may be the major host factor in
combating viral disease (9). Therefore, antiviral
chemotherapeutic agents that depress the host
cellular immune response might actually pre-
vent adequate elimination of the virus.
The present studies were undertaken to eval-
uate the effect of adenine arabinoside (ara-A)
on mechanisms of cellular immunity. Prelimi-
nary studies examined lymphocyte blastogenic
responses to mitogens and blastogenic and cyto-
toxic responses to cell cultures persistently
infected with herpes simplex virus types 1, and
2 (HSV-1 and -2) or varicella-zoster (V-Z) virus,
with or without ara-A added to the culture
material. Subsequent studies examined lym-
phocyte blastogenic and cytotoxic responses of
patients before, during, or after treatment with
ara-A.
MATERIALS AND METHODS
Preparation of lymphocytes. Lymphocytes were
separated from peripheral whole blood by centrifuga-
tion on a Hypaque-Ficoll gradient as prev.iously
described (12). The cell suspension was washed twice
with culture medium, and the lymphocytes were
adjusted to a concentration of 2 x 106/ml for determi-
nations of blastogenesis and 5 x 106/ml for cytotoxic-
ity assays in RPMI 1640 medium containing 20%
autologous serum.
Mitogen stimulation. Using a biopipette, 0.1 ml of
the lymphocyte suspension (2 x 101 lymphocytes) was
added to an equal volume of various concentrations of
the mitogens, phytohemagglutinin (PHA), pokeweed
(PWM), and concanavalin A (Con A), in one well of
sterile flat-bottom microtest plates (3040 Micro Test
II tissue culture plates, Falcon Plastics, Division of
Becton, Dickinson and Company, Oxnard, Calif.). All
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cultures were prepared in triplicate, and five dilutions
of PHA and PWM and four dilutions of Con A were
included along with control cultures containing lym-
phocytes incubated with medium alone. The plates
were covered with sterile plastic lids and cultures were
incubated for 72 h. Five hours prior to harvest, 0.05 ml
of RPMI 1640 medium containing 1 gCi of ['H ]thymi-
dine was added to each well. A harvesting apparatus
previously described (8) and technically refined for
our use (Biomedical Research Institute, Rockville,
Md.) was employed for separation of the stimulated
lymphocytes on glass-fiber filters, for washing of these
cells and for recovery of radioactive uptake. The glass
fiber disks were then dried in an oven and transferred
to vials containing 5 ml of scintillation fluid (TLA
in toluene, Beckman Instruments, Inc., Fullerton,
Calif.) for counting in a Beckman liquid scintillation
spectrometer. The average counts per minute of
triplicate samples were determined, and results were
expressed as a blastogenic index (BI): counts of
['H Ithymidine uptake per min for lymphocytes incu-
bated with mitogen divided by uptake after incuba-
tion with medium alone.
Cell cultures persistently infected with herpes
group viruses. Cell line MA-160 derived from human
prostate adenoma tissue was inoculated with the VR,
strain of HSV-1, the MS strain of HSV-2, or with V-Z
virus at a multiplicity of 1:1. The development of the
resulting three persistently infected cell lines is de-
scribed in a separate communication. A control cell
line of MA-160 and the infected lines were cultured
with Eagle minimum essential medium supple-
mented with 10% heat-inactivated fetal bovine serum,
Eagle non-essential amino acids, 1 mM sodium pyru-
vate, 100 U of penicillin per ml, and 100 lAg of
streptomycin per ml. For these studies, aliquots of the
three infected cell lines and the control line in
suspensions of 2 x 10" cells/ml were control rate
frozen with 7.5% dimethylsulfoxide as the cryoprotec-
tive agent and stored in the vapor phase of a liquid
nitrogen refrigerator.
Both the control and virus-infected cell lines were
monitored prior to use for surface membrane antigen
by indirect immunofluorescence. An average of 60 to
70% of the infected cells fluoresced; control cells did
not fluoresce.
Transfer of frozen cells from Bethesda, Maryland to
Fort Sam Houston, Texas was accomplished in nitro-
gen vapor transport refrigerators via air freight. On
arrival at the immunology laboratories ofBrooke Army
Medical Center, the ampoules were rapidly thawed in
a 37 C water bath, diluted in culture medium, and
washed three times in medium by centrifugation at
150 x g. The cells were then resuspended in RPMI
1640 medium and subsequently processed for the
blastogenic and cytotoxic assays as described below.
Assays of HSV-1-, HSV-2-, and V-Z-induced
lymphocyte blastogenesis. Methods were similar to
those employed for a one-way mixed lymphocyte
culture (11). Stimulating cells, however, included one
of the infected cultures and uninfected MA-160 cells.
These stimulating cells were concentrated to 2 x 10"
cells/ml and incubated for 1 h with 20 ug of mitomy-
cin C per ml. They were then washed three times and
resuspended in RPMI 1640 medium with N-2-hydrox-
yethyl-piperazine-N'-2'-ethanesulfonic acid buffer.
Lymphocytes were purified as described above and
adjusted to a final concentration of 2 x 106/ml in
RPMI 1640 containing 20% autologous serum. The
lymphocyte suspension (2 x 10' lymphocytes) in 0.1
ml was mixed with an equal volume of stimulating
cells in one well of microtest plates, as described for
mitogen stimulation.
Preliminary experiments were performed to deter-
mine the optimal incubation time and the optimal
concentration of stimulating cells for these assays of
lymphocyte blastogenesis. Maximum response was
observed after 5 to 6 days of incubation and with a
lymphocyte-to-stimulating cell ratio of 1:1. Therefore,
for the present assays 2 x 10' lymphocytes were
combined with 2 x 106 infected or control cells and
incubated for 5 days.
All cultures were prepared in triplicate. Twenty-
four hours prior to harvest, 0.05 ml of RPMI 1640
medium containing 1 ACi of ['H ]thymidine was added
to each well. Harvesting and counting of radioactive
uptake was accomplished as described above for
mitogen stimulation.
Assay of lymphocyte cytotoxicity. A "'Chromium
(G"Cr) microassay of lymphocytotoxicity to the cell
lines persistently infected with HSV-1, HSV-2, or V-Z
was used in these studies. Details of the microassay
were described previously (8). Briefly, this technique
examines lymphocyte-target cell interaction, employ-
ing the infected cell lines described above as the
target cells. The quantitative release of "'Cr from the
target cells is used as an index of lymphocyte-
mediated cytotoxicity against the infected cells.
Uninfected MA-160 cultures served as control target
cells to quantitate "'Cr release not attributable to the
virus itself. Target cell suspensions were labeled with
"'Cr (sodium chromate-Cr5l, New England Nuclear;
specific activity, 50 to 500 Ci/g) by incubating 107
cells in 1 ml of media containing 100 ACi of "Cr for 45
min as described previously (8).
An aliquot of 0.1 ml of lymphocytes (5 x 106) was
incubated with 0.1 ml of target cells (5 x 10' cells) in
flat-bottom microtest plates. Target cells were also
combined with 0.1 ml of media alone to determine
spontaneous release of "'Cr. All cultures on the
microtest plate were prepared in triplicate. The plates
were covered with sterile plastic lids and placed on a
rocker platform at 37 C in a 5% CO, atmosphere. The
cell suspensions were harvested after 24 h of incuba-
tion with the apparatus described above. The total
amount of "'Cr available for release was determined
by placing an aliquot of 0.1 ml of the target cell
suspension directly in a gamma-counting tube, and
zero time samples were also harvested at the time
incubation of the assay materials was begun. To
determine lymphocyte-mediated cytotoxicity specific
for HSV-1, spontaneous release of "'Cr from infected
target cells (I) and the control cells (C) was subtracted
from that released from the interaction of lympho-
cytes with infected target cells (IL) or control cells
(CL), respectively. The release at zero time was
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subtracted from the total amount of '1Cr in infected
cells (T) and control (TC) target cells to determine
the actual amount that was available for release dur-
ing the incubation period. Finally, the specific im-
mune release (SIR) was calculated by subtracting the
percentage of "'Cr release in the control target cells
from that released from the infected ones, according
to the following formula: %SIR = [IL - IIT, - zero
time, - CL - CITc - zero time, I x 100.
Study cases. To date 11 patients who have been
treated with ara-A have been studied with the assays
described. These assays included blastogenic re-
sponses to mitogens and blastogenic and cytotoxic
responses specific to the virus causing the patients'
infection. Data from four representative patients are
included in this report. These patients were an adult
with HSV-1 encephalitis, a neonate with generalized
HSV-2 infection, an adult with Hodgkin's disease and
a child with leukemia, both infected with V-Z virus.
Two of these four patients expired from the infection
during treatment; these deaths were not related to
administration of the drug.
Antiviral agents. ara-A was obtained from Parke,
Davis & Co., along with the phosphate-buffered saline
used as the placebo for their double blind treatment
protocol. Both the drug and the placebo were exam-
ined in vitro in the initial experiments. Cytosine
arabinoside (ara-C) (Cytosar, The Upjohn Co., Kala-
mazoo, Mich.) was also included in the in vitro
studies. These agents were diluted with RPMI so that
a fmal concentration of 3 sg/ml was achieved for
ara-A, the phosphate-buffered placebo, or ara-C, and
the effect of these products on mechanisms of cellular
immunity was examined.
RESULTS
Mitogen stimulation. In the preliminary ex-
periments, the influence of ara-A on lympho-
cyte blastogenic responses to mitogens was
examined (Fig. 1, 2, and 3). The experiments
were repeated five times with five different
lymphocyte donors, and results were averaged
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FIG. 1. In vitro lymphocyte blastogenesis after in-
cubation with PHA expressed as a blastogenic index:
counts per minute of ['H]thymidine uptake for lym-
phocytes incubated with PHA divided by uptake after
incubation with media alone.
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FIG. 2. In vitro lymphocyte blastogenesis after in-
cubation with PWM expressed as a blastogenic index:
counts per minute of [3H]thymidine uptake for lym-
phocytes incubated with PWM divided by uptake
after incubation with media alone.
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FiG. 3. In vitro lymphocyte blastogenesis after in-
cubation with Con A expressed as a blastogenic index:
counts per minute of ['H]thymidine uptake for lym-
phocytes incubated with Con A divided by uptake
after incubation with media alone.
for these three figures. The assays were con-
ducted using a 72-h incubation with a 5-h
['H]thymidine pulse. No significant differences
were observed for these assays when either 3 sg
of ara-A per ml was added to tissue culture
materials or an equivalent concentration of
placebo.
These assays of mitogen-induced lymphocyte
blastogenesis were also conducted with variable
incubation periods ranging from 1 to 7 days and,
likewise, no difference in responses was demon-
strated when ara-A in a concentration of 3
;g/ml was added to the culture medium.
Blastogenic and cytotoxic responses to
herpes group viruses. Tables 1 and 2 summa-
rize the results of lymphocyte blastogenesis and
lymphocyte cytotoxicity to herpes group-
infected target cells in the presence of ara-A.
Persistently infected cell lines included cells
infected with HSV-1, HSV-2, and V-Z virus. No
significant difference was noted for the assays
which included ara-A in the tissue culture
medium.
ara-C. In contrast to ara-A, ara-C severely
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depressed blastogenic responses to mitogens
and blastogenic responses to the cell lines per-
sistently infected with HSV-1, HSV-2, or V-Z.
The maximum BI after stimulation with PHA,
PWM, or Con A in the presence of ara-C
remained less than 3 for repeated determina-
TABLE 1. Lymphocyte Blastogenesis for herpes group
viruses in the presence of ara-A
Infected cell culture
Media contents
HSV-1 HSV-2 V-Z
Ara-A 12.1a 18.1 12.0
Placebo 12.3 15.8 11.5
Control 10.7 17.1 9.6
a Expressed as a blastogenic index: counts of
[3H]thymidine uptake per minute for lymphocytes
incubated with infected cells divided by uptake after
incubation with uninfected control cells.
TABLE 2. Lymphocyte cytotoxicity to herpes
group-infected target cells in the presence of ara-A
Infected cell cultures
Media contents
HSV-1 HSV-2 V-Z
Ara-A 27.8a 15.7 10.6
Placebo 24.9 10.0 6.1
Control 28.3 12.5 7.2
a Expressed as percent specific immune release of
51Cr attribtstable to intracellular virus.
tions. The maximum BI after incubation with
the herpes group viruses was less than 2. The
cytotoxic response to herpes group viruses was
also decreased to approximately one-half the
control value, but this appeared secondary to
toxic effects of ara-C on the cell lines them-
selves.
No patients were treated with ara-C, so
studies comparable to those undertaken for
patients on ara-A could not be obtained.
Patients treated with ara-A. Data from four
representative patients treated with ara-A and
studied with the assays described are presented
(Table 3). There were no statistically significant
differences in results obtained before, during, or
after therapy with ara-A. For these and other
patients studied by our laboratory, parameters
of cellular immunity have usually increased
during treatment with this antiviral chemother-
apeutic agent. No significant depression of
cellular immune responses has yet been ob-
served.
DISCUSSION
Historically, the most severe limiting factor
in the use of antiviral chemotherapeutic agents
has been their relatively high frequency of
severe toxic side effects. Both idoxuridine and
ara-C are known to produce bone marrow toxic-
ity (2, 4, 6). Leukopenia predisposes patients to
life-threatening bacterial, mycotic, and proto-
zoan diseases, and thrombocytopenia results in
TABLE 3. Cellular immune reactions of patients treated with ara-A
Mitogensa
Patient Age Agent Underlying disease Blastogenesisa , Cytotoxicityb (%)
PHA PWM Con A
1 38 years HSV-1 None 31c 72 67 9.2 12.1
4911 57 43 5.3 24.7
47e 60 60 12.3 31.4
2 4 days HSV-2 None 162 73 90 0.9 8.9
187 65 81 1.2 13.5
3 8 years V-Z Leukemia 87 43 73 7.8 23
99 57 65 15.3 26
68 51 54 13.1 17
4 23 years V-Z Hodgkin's 18 12 9 0.7 3
8 2 5 0.7 7
a Expressed as blastogenic index: counts of [3Hjthymidine uptake per minute for lymphocytes incubated
with mitogens or infected cells divided by uptake after incubation with media or uninfected control cells, respec-
tively.
b Responses specific for the virus with which the patient was infected.
c Before treatment.
dDuring treatment.
e After treatment.
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serious risk of uncontrolled hemorrhage. Im-
mune suppression of the humoral immune sys-
tem predisposes patients to risk from secondary
infections (1, 3, 10). Gastrointestinal and cen-
tral nervous system toxicity also limit the
usefulness of some of the potential antiviral
compounds. Ara-C and idoxuridine have both
been shown to inhibit cerebellar development in
fetal and young animals, causing serious con-
cern in recommending their use in neonatal
deoxyribonucleic acid viral disease (5). Minor
but irritating side effects such as oral mucosal
ulceration and alopecia are unfortunately com-
mon.
Experience to date with parenteral adminis-
tration of ara-A has been strikingly devoid of
serious toxic side effects. This has been the
experience even though, in contrast to ara-C
and idoxuridine, ara-A has a much longer
half-life of antiviral activity, principally af-
forded by the activity of its primary hypoxan-
thine derivative metabolite (P. E. Borondy, D.
R. Mourer, T. Chang, and A. J. Glazko, Fed.
Proc. 32:777, 1973).
Since full recovery from severe viral infec-
tions appears to require at least partial host
immune competence, it is imperative that anti-
viral chemotherapeutic agents not suppress
these host responses. Previous reports have
demonstrated that therapeutic doses of ara-A
do not produce immunosuppression in animals
(7; Z. S. Zam, Y. M. Centifanto, and H. E.
Kaufman, Prog. Abstr. Intersci. Conf. Antimi-
crob. Agents Chemother., 14th, San Francisco,
Calif., Abstr. 139, 1974), and further investiga-
tion has revealed that antibody production is
not impaired after therapy with ara-A (Zam et
al., Progr. Abstr. Intersci. Conf. Antimicrob.
Agents Chemother, 14th, San Francisco, Calif.,
Abstr. 139, 1974).
The present study has evaluated assays of
cellular immunity when ara-A is added to in
vitro materials and has examined mechanisms
of cellular immunity in patients treated with
ara-A for various deoxyribonucleic acid virus
infection. With the assays employed there is no
evidence that the antiviral agent, ara-A, im-
pairs these host defense mechanisms.
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